Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Type 2 Diabetes clinical trials

Directory of U.S. ClinicalTrials.gov public records for Type 2 Diabetes. Browse Type 2 Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 19, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
620
Shown on this page
12
Current sort
Recently updated
Condition scope
Type 2 Diabetes
Additional filters apply within this condition.
The trial list below is retrieved from the live ClinicalTrials.gov search API for Type 2 Diabetes. Results on this page are currently sorted by Recently updated.

How Type 2 Diabetes studies are organized in the registry

Type 2 diabetes records also appear under generic “diabetes” and the abbreviation T2DM, so checking both phrasings gives fuller coverage. The portfolio spans drug trials, lifestyle programs, and large cardiovascular-outcome studies; the study-type filter separates the observational cohorts from interventional trials.

Terms that often appear in related listings
T2DM metformin cardiovascular outcomes lifestyle intervention

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Type 2 Diabetes. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 620 matching trials for Type 2 Diabetes.
Live ClinicalTrials.gov results.
Active filters: "metformin" Clear condition filters
Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
64
States / cities
Phoenix, Arizona • Canoga Park, California • Escondido, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

NCT07340320
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

NCT06323161
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Fresno, California • Northridge, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

NCT06534411
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
54
States / cities
Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cagrilintide, Semaglutide, Tirzepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
117
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed No phase listed Observational

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

NCT00445627
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Metformin, Insulin, Nutrition counseling, Exercise counseling
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 25 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 19, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

NCT05035082
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
semaglutide, oral glucose-lowering medications (commercially available)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 19, 2026, 5:30 PM EDT

About this Type 2 Diabetes clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Type 2 Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Type 2 Diabetes.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Type 2 Diabetes.